Literature DB >> 24552677

Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project results.

Louise A Brinton1, Michael B Cook, Valerie McCormack, Kenneth C Johnson, Håkan Olsson, John T Casagrande, Rosie Cooke, Roni T Falk, Susan M Gapstur, Mia M Gaudet, J Michael Gaziano, Georgios Gkiokas, Pascal Guénel, Brian E Henderson, Albert Hollenbeck, Ann W Hsing, Laurence N Kolonel, Claudine Isaacs, Jay H Lubin, Karin B Michels, Eva Negri, Dominick Parisi, Eleni Th Petridou, Malcolm C Pike, Elio Riboli, Howard D Sesso, Kirk Snyder, Anthony J Swerdlow, Dimitrios Trichopoulos, Giske Ursin, Piet A van den Brandt, Stephen K Van Den Eeden, Elisabete Weiderpass, Walter C Willett, Marianne Ewertz, David B Thomas.   

Abstract

BACKGROUND: The etiology of male breast cancer is poorly understood, partly because of its relative rarity. Although genetic factors are involved, less is known regarding the role of anthropometric and hormonally related risk factors.
METHODS: In the Male Breast Cancer Pooling Project, a consortium of 11 case-control and 10 cohort investigations involving 2405 case patients (n = 1190 from case-control and n = 1215 from cohort studies) and 52013 control subjects, individual participant data were harmonized and pooled. Unconditional logistic regression generated study design-specific (case-control/cohort) odds ratios (ORs) and 95% confidence intervals (CIs), with exposure estimates combined using fixed effects meta-analysis. All statistical tests were two-sided.
RESULTS: Risk was statistically significantly associated with weight (highest/lowest tertile: OR = 1.36; 95% CI = 1.18 to 1.57), height (OR = 1.18; 95% CI = 1.01 to 1.38), and body mass index (BMI; OR = 1.30; 95% CI = 1.12 to 1.51), with evidence that recent rather than distant BMI was the strongest predictor. Klinefelter syndrome (OR = 24.7; 95% CI = 8.94 to 68.4) and gynecomastia (OR = 9.78; 95% CI = 7.52 to 12.7) were also statistically significantly associated with risk, relations that were independent of BMI. Diabetes also emerged as an independent risk factor (OR = 1.19; 95% CI = 1.04 to 1.37). There were also suggestive relations with cryptorchidism (OR = 2.18; 95% CI = 0.96 to 4.94) and orchitis (OR = 1.43; 95% CI = 1.02 to 1.99). Although age at onset of puberty and histories of infertility were unrelated to risk, never having had children was statistically significantly related (OR = 1.29; 95% CI = 1.01 to 1.66). Among individuals diagnosed at older ages, a history of fractures was statistically significantly related (OR = 1.41; 95% CI = 1.07 to 1.86).
CONCLUSIONS: Consistent findings across case-control and cohort investigations, complemented by pooled analyses, indicated important roles for anthropometric and hormonal risk factors in the etiology of male breast cancer. Further investigation should focus on potential roles of endogenous hormones.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24552677      PMCID: PMC3975166          DOI: 10.1093/jnci/djt465

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  53 in total

1.  Factors influencing the optimal control-to-case ratio in matched case-control studies.

Authors:  S Hennessy; W B Bilker; J A Berlin; B L Strom
Journal:  Am J Epidemiol       Date:  1999-01-15       Impact factor: 4.897

2.  Risk of breast cancer in men with liver cirrhosis.

Authors:  H T Sørensen; S Friis; J H Olsen; A M Thulstrup; L Mellemkjaer; M Linet; D Trichopoulos; H Vilstrup; J Olsen
Journal:  Am J Gastroenterol       Date:  1998-02       Impact factor: 10.864

3.  A large-scale prospective cohort study on diet and cancer in The Netherlands.

Authors:  P A van den Brandt; R A Goldbohm; P van 't Veer; A Volovics; R J Hermus; F Sturmans
Journal:  J Clin Epidemiol       Date:  1990       Impact factor: 6.437

4.  Male breast cancer in Israel. Selected epidemiological and clinical aspects.

Authors:  B Modan; U Mintz; J Finkelman
Journal:  J Chronic Dis       Date:  1970-06

5.  Prevalence of Klinefelter's syndrome in male breast cancer patients.

Authors:  R Hultborn; C Hanson; I Köpf; I Verbiené; E Warnhammar; A Weimarck
Journal:  Anticancer Res       Date:  1997 Nov-Dec       Impact factor: 2.480

6.  Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

Authors:  P C Prorok; G L Andriole; R S Bresalier; S S Buys; D Chia; E D Crawford; R Fogel; E P Gelmann; F Gilbert; M A Hasson; R B Hayes; C C Johnson; J S Mandel; A Oberman; B O'Brien; M M Oken; S Rafla; D Reding; W Rutt; J L Weissfeld; L Yokochi; J K Gohagan
Journal:  Control Clin Trials       Date:  2000-12

7.  Endogenous oestrogens and breast cancer risk in premenopausal and postmenopausal women.

Authors:  Timothy J Key
Journal:  Steroids       Date:  2011-04-06       Impact factor: 2.668

Review 8.  A review of the diagnosis and management of male breast cancer.

Authors:  Sharon H Giordano
Journal:  Oncologist       Date:  2005-08

9.  Body mass index and risk of prostate cancer in U.S. health professionals.

Authors:  Edward Giovannucci; Eric B Rimm; Yan Liu; Michael Leitzmann; Kana Wu; Meir J Stampfer; Walter C Willett
Journal:  J Natl Cancer Inst       Date:  2003-08-20       Impact factor: 13.506

10.  Men's health, low testosterone, and diabetes: individualized treatment and a multidisciplinary approach.

Authors:  Donna Rice; Robert E Brannigan; R Keith Campbell; Shari Fine; Leonard Jack; Joseph B Nelson; Janet Regan-Klich
Journal:  Diabetes Educ       Date:  2008 Nov-Dec       Impact factor: 2.140

View more
  40 in total

Review 1.  The Epidemiology of Male Breast Cancer.

Authors:  Raina M Ferzoco; Kathryn J Ruddy
Journal:  Curr Oncol Rep       Date:  2016-01       Impact factor: 5.075

2.  Prediagnostic Sex Steroid Hormones in Relation to Male Breast Cancer Risk.

Authors:  Louise A Brinton; Tim J Key; Laurence N Kolonel; Karin B Michels; Howard D Sesso; Giske Ursin; Stephen K Van Den Eeden; Shannon N Wood; Roni T Falk; Dominick Parisi; Chantal Guillemette; Patrick Caron; Véronique Turcotte; Laurel A Habel; Claudine J Isaacs; Elio Riboli; Elisabete Weiderpass; Michael B Cook
Journal:  J Clin Oncol       Date:  2015-05-11       Impact factor: 44.544

3.  Body Fatness and Cancer--Viewpoint of the IARC Working Group.

Authors:  Béatrice Lauby-Secretan; Chiara Scoccianti; Dana Loomis; Yann Grosse; Franca Bianchini; Kurt Straif
Journal:  N Engl J Med       Date:  2016-08-25       Impact factor: 91.245

Review 4.  Progesterone and Breast Cancer.

Authors:  Britton Trabert; Mark E Sherman; Nagarajan Kannan; Frank Z Stanczyk
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

5.  Male breast cancer: a rare disease that might uncover underlying pathways of breast cancer.

Authors:  Laura Ottini
Journal:  Nat Rev Cancer       Date:  2014-10       Impact factor: 60.716

6.  A Case of Male Breast Cancer with a BRCA Gene Mutation.

Authors:  Martin A Benjamin; Adam I Riker
Journal:  Ochsner J       Date:  2015

7.  Physical Activity and Risk of Male Breast Cancer.

Authors:  Hannah Arem; Louise A Brinton; Steven C Moore; Susan M Gapstur; Laurel A Habel; Kenneth Johnson; Laurence N Kolonel; Valerie A McCormack; Karin B Michels; Howard D Sesso; Giske Ursin; Stephen K Van Den Eeden; Elisabete Weiderpass; Michael B Cook; Charles E Matthews
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-09-24       Impact factor: 4.254

Review 8.  Breast Cancer Prevention: Current Approaches and Future Directions.

Authors:  Edward R Sauter
Journal:  Eur J Breast Health       Date:  2018-04-01

9.  Influence of Age on the Clinical Outcome of Breast Cancer for Men and the Development of Second Primary Cancers.

Authors:  Patricia A Cronin; Anya Romanoff; Emily C Zabor; Michelle Stempel; Anne Eaton; Lillian M Smyth; Alice Y Ho; Monica Morrow; Mahmoud El-Tamer; Mary L Gemignani
Journal:  Ann Surg Oncol       Date:  2018-10-08       Impact factor: 5.344

Review 10.  Environmental endocrine disruptors: Effects on the human male reproductive system.

Authors:  M F Sweeney; N Hasan; A M Soto; C Sonnenschein
Journal:  Rev Endocr Metab Disord       Date:  2015-12       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.